{"hands_on_practices": [{"introduction": "The threat posed by Carbapenemase-producing Enterobacterales (CPE) is rooted in the remarkable catalytic efficiency of their enzymes. To effectively combat them, we must first quantify their power. This practice [@problem_id:4616627] places you in the role of a biochemist, tasking you with analyzing hypothetical initial-rate data to determine the Michaelis-Menten parameters $K_m$ and $k_{\\mathrm{cat}}$. Through this exercise, you will apply fundamental principles of enzyme kinetics to measure the potency of a carbapenemase, a critical step in evaluating the scale of the resistance challenge.", "problem": "A purified preparation of Klebsiella pneumoniae carbapenemase (KPC) from a Carbapenemase-producing Enterobacterales (CPE) isolate is assayed for hydrolysis of imipenem at $25\\,^{\\circ}\\mathrm{C}$ in buffered aqueous solution. Under initial-rate conditions with negligible product accumulation and assuming single-substrate Michaelis–Menten kinetics, the initial reaction velocity $v_{0}$ is measured at several imipenem concentrations $[S]$ with a fixed total active enzyme concentration $[E]_{t}$. The measured dataset is:\n$[E]_{t} = 5\\,\\mathrm{nM}$; $[S] = 10\\,\\mu\\mathrm{M} \\rightarrow v_{0} = 0.08333\\,\\mu\\mathrm{M}\\,\\mathrm{s}^{-1}$; $[S] = 20\\,\\mu\\mathrm{M} \\rightarrow v_{0} = 0.142857\\,\\mu\\mathrm{M}\\,\\mathrm{s}^{-1}$; $[S] = 50\\,\\mu\\mathrm{M} \\rightarrow v_{0} = 0.25\\,\\mu\\mathrm{M}\\,\\mathrm{s}^{-1}$; $[S] = 100\\,\\mu\\mathrm{M} \\rightarrow v_{0} = 0.333333\\,\\mu\\mathrm{M}\\,\\mathrm{s}^{-1}$; $[S] = 200\\,\\mu\\mathrm{M} \\rightarrow v_{0} = 0.4\\,\\mu\\mathrm{M}\\,\\mathrm{s}^{-1}$.\n\nUsing the framework of steady-state enzyme kinetics appropriate for the Michaelis–Menten model and the provided initial-rate data, determine the Michaelis–Menten parameters $K_{m}$ and $k_{\\mathrm{cat}}$ for KPC hydrolysis of imipenem, and then compute the catalytic efficiency $k_{\\mathrm{cat}}/K_{m}$. Express your final catalytic efficiency in $\\mathrm{M}^{-1}\\,\\mathrm{s}^{-1}$ and round your final answer to three significant figures. The final answer must be a single number.", "solution": "The appropriate fundamental base for analyzing these data is the steady-state Michaelis–Menten model for a single-substrate enzyme-catalyzed reaction. Under initial-rate conditions with negligible product and assuming that the enzyme–substrate complex reaches a steady state rapidly relative to turnover, the initial velocity $v_{0}$ as a function of substrate concentration $[S]$ can be described by the Michaelis–Menten equation\n$$\nv_{0} = \\frac{V_{\\max}[S]}{K_{m} + [S]},\n$$\nwhere $V_{\\max} = k_{\\mathrm{cat}}[E]_{t}$, $K_{m}$ is the Michaelis constant, and $k_{\\mathrm{cat}}$ is the catalytic turnover number.\n\nTo extract $K_{m}$ and $V_{\\max}$ from initial-rate data, one well-tested approach is to use the Lineweaver–Burk double-reciprocal linearization, which follows from algebraic manipulation of the Michaelis–Menten equation:\n$$\n\\frac{1}{v_{0}} = \\frac{K_{m}}{V_{\\max}} \\cdot \\frac{1}{[S]} + \\frac{1}{V_{\\max}}.\n$$\nThis is of the form $y = m x + b$ with $y = 1/v_{0}$, $x = 1/[S]$, slope $m = K_{m}/V_{\\max}$, and intercept $b = 1/V_{\\max}$.\n\nCompute the reciprocal coordinates using the supplied data, keeping substrate in $\\mu\\mathrm{M}$ and velocity in $\\mu\\mathrm{M}\\,\\mathrm{s}^{-1}$ so that $K_{m}$ will be in $\\mu\\mathrm{M}$ and $V_{\\max}$ in $\\mu\\mathrm{M}\\,\\mathrm{s}^{-1}$:\n\n- For $[S] = 10\\,\\mu\\mathrm{M}$ and $v_{0} = 0.08333\\,\\mu\\mathrm{M}\\,\\mathrm{s}^{-1}$, we have\n$$\n\\frac{1}{[S]} = \\frac{1}{10}\\,\\mu\\mathrm{M}^{-1} = 0.1\\,\\mu\\mathrm{M}^{-1}, \\quad \\frac{1}{v_{0}} = \\frac{1}{0.08333}\\,\\mathrm{s}\\,\\mu\\mathrm{M}^{-1} \\approx 12\\,\\mathrm{s}\\,\\mu\\mathrm{M}^{-1}.\n$$\n- For $[S] = 20\\,\\mu\\mathrm{M}$ and $v_{0} = 0.142857\\,\\mu\\mathrm{M}\\,\\mathrm{s}^{-1}$,\n$$\n\\frac{1}{[S]} = 0.05\\,\\mu\\mathrm{M}^{-1}, \\quad \\frac{1}{v_{0}} \\approx 7\\,\\mathrm{s}\\,\\mu\\mathrm{M}^{-1}.\n$$\n- For $[S] = 50\\,\\mu\\mathrm{M}$ and $v_{0} = 0.25\\,\\mu\\mathrm{M}\\,\\mathrm{s}^{-1}$,\n$$\n\\frac{1}{[S]} = 0.02\\,\\mu\\mathrm{M}^{-1}, \\quad \\frac{1}{v_{0}} = 4\\,\\mathrm{s}\\,\\mu\\mathrm{M}^{-1}.\n$$\n- For $[S] = 100\\,\\mu\\mathrm{M}$ and $v_{0} = 0.333333\\,\\mu\\mathrm{M}\\,\\mathrm{s}^{-1}$,\n$$\n\\frac{1}{[S]} = 0.01\\,\\mu\\mathrm{M}^{-1}, \\quad \\frac{1}{v_{0}} \\approx 3\\,\\mathrm{s}\\,\\mu\\mathrm{M}^{-1}.\n$$\n- For $[S] = 200\\,\\mu\\mathrm{M}$ and $v_{0} = 0.4\\,\\mu\\mathrm{M}\\,\\mathrm{s}^{-1}$,\n$$\n\\frac{1}{[S]} = 0.005\\,\\mu\\mathrm{M}^{-1}, \\quad \\frac{1}{v_{0}} = 2.5\\,\\mathrm{s}\\,\\mu\\mathrm{M}^{-1}.\n$$\n\nThe points $\\left( \\frac{1}{[S]}, \\frac{1}{v_{0}} \\right)$ lie on a line consistent with the Lineweaver–Burk relationship. Using any two points to determine the slope and intercept (the data are internally consistent), take, for example, the points at $[S] = 50\\,\\mu\\mathrm{M}$ and $[S] = 100\\,\\mu\\mathrm{M}$:\n$$\nx_{1} = 0.02\\,\\mu\\mathrm{M}^{-1}, \\quad y_{1} = 4\\,\\mathrm{s}\\,\\mu\\mathrm{M}^{-1}; \\quad x_{2} = 0.01\\,\\mu\\mathrm{M}^{-1}, \\quad y_{2} = 3\\,\\mathrm{s}\\,\\mu\\mathrm{M}^{-1}.\n$$\nThe slope $m$ is\n$$\nm = \\frac{y_{2} - y_{1}}{x_{2} - x_{1}} = \\frac{3 - 4}{0.01 - 0.02}\\,\\mathrm{s} = \\frac{-1}{-0.01}\\,\\mathrm{s} = 100\\,\\mathrm{s}.\n$$\nThe intercept $b$ is obtained from $y = m x + b$; using $x_{2}, y_{2}$:\n$$\nb = y_{2} - m x_{2} = 3 - 100 \\cdot 0.01 = 3 - 1 = 2\\,\\mathrm{s}\\,\\mu\\mathrm{M}^{-1}.\n$$\nTherefore,\n$$\nV_{\\max} = \\frac{1}{b} = \\frac{1}{2}\\,\\mu\\mathrm{M}\\,\\mathrm{s}^{-1} = 0.5\\,\\mu\\mathrm{M}\\,\\mathrm{s}^{-1},\n$$\nand\n$$\nK_{m} = m V_{\\max} = 100\\,\\mathrm{s} \\times 0.5\\,\\mu\\mathrm{M}\\,\\mathrm{s}^{-1} = 50\\,\\mu\\mathrm{M}.\n$$\n\nNext, compute the catalytic turnover number $k_{\\mathrm{cat}}$ using $V_{\\max} = k_{\\mathrm{cat}} [E]_{t}$. First convert the enzyme concentration to the same molar unit as $V_{\\max}$; since $V_{\\max}$ is in $\\mu\\mathrm{M}\\,\\mathrm{s}^{-1}$ and $[E]_{t} = 5\\,\\mathrm{nM}$,\n$$\n[E]_{t} = 5\\,\\mathrm{nM} = 0.005\\,\\mu\\mathrm{M}.\n$$\nThus,\n$$\nk_{\\mathrm{cat}} = \\frac{V_{\\max}}{[E]_{t}} = \\frac{0.5\\,\\mu\\mathrm{M}\\,\\mathrm{s}^{-1}}{0.005\\,\\mu\\mathrm{M}} = 100\\,\\mathrm{s}^{-1}.\n$$\n\nFinally, compute the catalytic efficiency $k_{\\mathrm{cat}}/K_{m}$. Using $K_{m} = 50\\,\\mu\\mathrm{M}$,\n$$\n\\frac{k_{\\mathrm{cat}}}{K_{m}} = \\frac{100\\,\\mathrm{s}^{-1}}{50\\,\\mu\\mathrm{M}} = 2\\,\\mathrm{s}^{-1}\\,\\mu\\mathrm{M}^{-1}.\n$$\nConvert $\\mu\\mathrm{M}^{-1}$ to $\\mathrm{M}^{-1}$ using $1\\,\\mu\\mathrm{M} = 10^{-6}\\,\\mathrm{M}$, hence $1\\,\\mu\\mathrm{M}^{-1} = 10^{6}\\,\\mathrm{M}^{-1}$:\n$$\n2\\,\\mathrm{s}^{-1}\\,\\mu\\mathrm{M}^{-1} = 2 \\times 10^{6}\\,\\mathrm{M}^{-1}\\,\\mathrm{s}^{-1}.\n$$\n\nRounding to three significant figures as required, the catalytic efficiency is\n$$\n2.00 \\times 10^{6}\\,\\mathrm{M}^{-1}\\,\\mathrm{s}^{-1}.\n$$", "answer": "$$\\boxed{2.00 \\times 10^{6}}$$", "id": "4616627"}, {"introduction": "Moving from the biochemistry bench to the clinical microbiology lab, the next challenge is to identify the precise cause of resistance in a bacterial isolate. Not all carbapenem resistance is due to carbapenemases, and distinguishing the mechanism is vital for guiding treatment and infection control. This problem [@problem_id:4616616] presents a realistic clinical scenario where you must interpret a panel of antimicrobial susceptibility results and specialized test data. This exercise will sharpen your diagnostic reasoning and demonstrate how laboratory scientists unravel complex resistance phenotypes to provide actionable information.", "problem": "A clinical laboratory isolates an Enterobacterales species from a bloodstream infection and performs susceptibility testing alongside targeted phenotypic assays. The foundational concepts are as follows: beta-lactam antibiotics reach periplasmic penicillin-binding proteins through outer membrane porins (Outer Membrane Porin (OMP)), and their activity is governed by access plus stability against hydrolysis. The Minimal Inhibitory Concentration (MIC) is the lowest antimicrobial concentration that prevents visible growth. Ertapenem, imipenem, and meropenem are carbapenems with distinct physicochemical properties and porin usage. Extended-Spectrum Beta-Lactamase (ESBL) and AmpC beta-lactamase (AmpC) hydrolyze many cephalosporins but do not efficiently hydrolyze carbapenems, whereas carbapenemases actively hydrolyze carbapenems. Outer membrane porin alterations reduce carbapenem influx, which disproportionately affects ertapenem relative to imipenem and meropenem. The Clinical and Laboratory Standards Institute (CLSI) breakpoints for Enterobacterales commonly applied are: ertapenem susceptible if MIC $\\le 0.5\\,\\mu\\text{g/mL}$, intermediate at $1\\,\\mu\\text{g/mL}$, and resistant at $\\ge 2\\,\\mu\\text{g/mL}$; meropenem and imipenem susceptible if MIC $\\le 1\\,\\mu\\text{g/mL}$, intermediate at $2\\,\\mu\\text{g/mL}$, and resistant at $\\ge 4\\,\\mu\\text{g/mL}$. Carbapenemase detection tests include the Modified Carbapenem Inactivation Method (mCIM), the EDTA-modified CIM (eCIM) to infer metallo-beta-lactamases, and the Carbapenemase Nordmann–Poirel (Carba NP) test; immunochromatographic assays can detect specific carbapenemase families such as Klebsiella pneumoniae carbapenemase (KPC), New Delhi metallo-beta-lactamase (NDM), Verona integron-encoded metallo-beta-lactamase (VIM), and Oxacillinase-48 (OXA-48-like).\n\nUsing these bases, choose the option that is most consistent with ertapenem resistance attributable to porin alterations together with ESBL or AmpC activity, rather than resistance mediated by carbapenemase production. Select the pattern whose embedded laboratory discriminator most clearly separates these entities.\n\nA. An Enterobacter cloacae complex isolate with ertapenem MIC $4\\,\\mu\\text{g/mL}$ (resistant), meropenem MIC $0.5\\,\\mu\\text{g/mL}$ (susceptible), imipenem MIC $1\\,\\mu\\text{g/mL}$ (susceptible), ceftriaxone MIC $>64\\,\\mu\\text{g/mL}$ (resistant), cefoxitin MIC $>32\\,\\mu\\text{g/mL}$ (resistant). Beta-lactamase inhibitor assays show synergy with clavulanate for oxyimino-cephalosporins and boronic acid synergy is positive. mCIM negative, eCIM negative, Carba NP negative.\n\nB. A Klebsiella pneumoniae isolate with ertapenem MIC $4\\,\\mu\\text{g/mL}$ (resistant), meropenem MIC $8\\,\\mu\\text{g/mL}$ (resistant), imipenem MIC $8\\,\\mu\\text{g/mL}$ (resistant). mCIM positive, eCIM negative. Immunochromatographic assay positive for KPC.\n\nC. An Escherichia coli isolate with ertapenem MIC $4\\,\\mu\\text{g/mL}$ (resistant), meropenem MIC $1\\,\\mu\\text{g/mL}$ (susceptible), imipenem MIC $1\\,\\mu\\text{g/mL}$ (susceptible). mCIM positive, Carba NP positive. Immunochromatographic assay positive for OXA-48-like.\n\nD. An Enterobacterales isolate with ertapenem MIC $4\\,\\mu\\text{g/mL}$ (resistant), meropenem MIC $0.5\\,\\mu\\text{g/mL}$ (susceptible), imipenem MIC $1\\,\\mu\\text{g/mL}$ (susceptible). mCIM negative, eCIM negative. Immunochromatographic assay positive for OXA-48-like; temocillin MIC $>128\\,\\mu\\text{g/mL}$.", "solution": "The problem requires the identification of a laboratory profile most consistent with ertapenem resistance in an Enterobacterales isolate due to the combined effect of outer membrane porin (OMP) alteration and the presence of an Extended-Spectrum Beta-Lactamase (ESBL) or an AmpC-type beta-lactamase, as opposed to resistance mediated by a carbapenemase.\n\nFirst, let us formalize the expected phenotype for the target mechanism (Porin Alteration + ESBL/AmpC):\n1.  **Antimicrobial Susceptibility Pattern**: The problem states that OMP alterations disproportionately affect ertapenem. This implies that the isolate's Minimal Inhibitory Concentration (MIC) for ertapenem will be elevated into the resistant range, while the MICs for imipenem and meropenem will remain significantly lower, likely in the susceptible or intermediate range.\n    *   Ertapenem: Resistant (MIC $\\ge 2\\,\\mu\\text{g/mL}$).\n    *   Imipenem/Meropenem: Susceptible (MIC $\\le 1\\,\\mu\\text{g/mL}$) or Intermediate (MIC $= 2\\,\\mu\\text{g/mL}$). This differential susceptibility (Ertapenem-R, Imipenem/Meropenem-S/I) is the hallmark of this mechanism.\n    *   The presence of an ESBL or AmpC will confer resistance to many cephalosporins (e.g., ceftriaxone, cefepime) and, in the case of AmpC, cephamycins (e.g., cefoxitin).\n2.  **Carbapenemase Detection Tests**: Since the resistance mechanism is not a carbapenemase, all tests designed to specifically detect carbapenemase enzymes or their activity should be negative.\n    *   Modified Carbapenem Inactivation Method (mCIM): Negative.\n    *   Carbapenemase Nordmann–Poirel (Carba NP) test: Negative.\n    *   Immunochromatographic assays (ICAs) for specific carbapenemases (KPC, NDM, VIM, OXA-48-like): Negative.\n\nNow, we will evaluate each option against this expected profile.\n\n**Option A Analysis:**\n*   **Isolate**: *Enterobacter cloacae* complex isolate. This species is well-known for producing a chromosomal AmpC beta-lactamase that can be overexpressed.\n*   **Antibiogram**:\n    *   Ertapenem MIC is $4\\,\\mu\\text{g/mL}$ (Resistant, as $4 \\ge 2$).\n    *   Meropenem MIC is $0.5\\,\\mu\\text{g/mL}$ (Susceptible, as $0.5 \\le 1$).\n    *   Imipenem MIC is $1\\,\\mu\\text{g/mL}$ (Susceptible, as $1 \\le 1$).\n    This pattern of ertapenem-resistant but meropenem/imipenem-susceptible is precisely what is expected from significant porin alteration.\n    *   Ceftriaxone MIC $>64\\,\\mu\\text{g/mL}$ (Resistant) and Cefoxitin MIC $>32\\,\\mu\\text{g/mL}$ (Resistant). Resistance to cefoxitin is a classic indicator of AmpC beta-lactamase activity.\n*   **Enzyme/Inhibitor Profile**:\n    *   \"Beta-lactamase inhibitor assays show synergy with clavulanate for oxyimino-cephalosporins\": This is characteristic of an ESBL. It is possible for an organism to co-produce ESBL and AmpC.\n    *   \"boronic acid synergy is positive\": Boronic acid derivatives inhibit both AmpC and KPC-type carbapenemases. Given the context, this strongly suggests AmpC activity.\n*   **Carbapenemase Tests**: mCIM negative, eCIM negative, Carba NP negative. The negativity of all these specific tests definitively rules out the presence of a hydrolytically significant carbapenemase.\n*   **Conclusion**: This profile perfectly aligns with the target mechanism. The differential carbapenem MICs point to porin loss, the cephalosporin resistance and positive boronic acid synergy point to an AmpC enzyme, and the negative carbapenemase test results confirm the absence of a carbapenemase. This provides a clear laboratory picture separating this mechanism from CRE.\n\nVerdict: **Correct**.\n\n**Option B Analysis:**\n*   **Isolate**: *Klebsiella pneumoniae*.\n*   **Antibiogram**:\n    *   Ertapenem MIC is $4\\,\\mu\\text{g/mL}$ (Resistant).\n    *   Meropenem MIC is $8\\,\\mu\\text{g/mL}$ (Resistant, as $8 \\ge 4$).\n    *   Imipenem MIC is $8\\,\\mu\\text{g/mL}$ (Resistant, as $8 \\ge 4$).\n    Resistance to all three carbapenems, with high MICs for meropenem and imipenem, is the classic presentation of a potent carbapenemase producer.\n*   **Carbapenemase Tests**:\n    *   mCIM positive: Confirms carbapenem-hydrolyzing activity.\n    *   eCIM negative: Rules out a metallo-beta-lactamase (MBL).\n    *   Immunochromatographic assay positive for KPC: Identifies the specific enzyme as *Klebsiella pneumoniae* carbapenemase (KPC), a serine carbapenemase.\n*   **Conclusion**: This profile is a clear-cut case of resistance mediated by a KPC carbapenemase. This is the alternative mechanism that the question asks to exclude.\n\nVerdict: **Incorrect**.\n\n**Option C Analysis:**\n*   **Isolate**: *Escherichia coli*.\n*   **Antibiogram**:\n    *   Ertapenem MIC is $4\\,\\mu\\text{g/mL}$ (Resistant).\n    *   Meropenem MIC is $1\\,\\mu\\text{g/mL}$ (Susceptible).\n    *   Imipenem MIC is $1\\,\\mu\\text{g/mL}$ (Susceptible).\n    This MIC profile, on its own, mimics the porin loss + ESBL/AmpC phenotype. However, we must consider the specific enzyme tests.\n*   **Carbapenemase Tests**:\n    *   mCIM positive and Carba NP positive: Both tests are positive, unequivocally indicating the presence of a carbapenemase.\n    *   Immunochromatographic assay positive for OXA-48-like: Identifies the specific carbapenemase. OXA-48-like enzymes are known to hydrolyze ertapenem more effectively than imipenem/meropenem and often require concurrent porin loss to express high-level resistance, which explains the observed MIC pattern.\n*   **Conclusion**: Despite the carbapenem MIC pattern, the definitive positive results from multiple carbapenemase assays confirm that resistance is mediated by a carbapenemase (OXA-48-like).\n\nVerdict: **Incorrect**.\n\n**Option D Analysis:**\n*   **Isolate**: An Enterobacterales isolate.\n*   **Antibiogram**:\n    *   Ertapenem MIC is $4\\,\\mu\\text{g/mL}$ (Resistant).\n    *   Meropenem MIC is $0.5\\,\\mu\\text{g/mL}$ (Susceptible).\n    *   Imipenem MIC is $1\\,\\mu\\text{g/mL}$ (Susceptible).\n    This MIC pattern is again suggestive of the non-carbapenemase mechanism.\n*   **Carbapenemase Tests  Other Indicators**:\n    *   mCIM negative and eCIM negative: This seems to rule out many carbapenemases.\n    *   However, the immunochromatographic assay is positive for OXA-48-like. This is a direct, specific detection of the enzyme protein itself.\n    *   Furthermore, the temocillin MIC is $>128\\,\\mu\\text{g/mL}$. High-level resistance to temocillin is a highly sensitive and specific phenotypic marker for the presence of OXA-48-like enzymes.\n*   **Conclusion**: The negative mCIM result is a known pitfall in detecting OXA-48-like enzymes, which are weak carbapenem hydrolyzers. The combination of a positive specific ICA for OXA-48-like and high-level temocillin resistance provides conclusive evidence that a carbapenemase is present and is the cause of resistance. Therefore, this option represents resistance mediated by a carbapenemase.\n\nVerdict: **Incorrect**.\n\nIn summary, Option A is the only profile where the complete set of laboratory data (differential carbapenem MICs, evidence for AmpC, and universally negative specific carbapenemase tests) is fully consistent with ertapenem resistance due to porin alteration plus an AmpC enzyme, without the involvement of a carbapenemase.", "answer": "$$\\boxed{A}$$", "id": "4616616"}, {"introduction": "Once a CRE infection is diagnosed and the pathogen's Minimum Inhibitory Concentration (MIC) is known, the focus shifts to the patient's treatment. Simply knowing the MIC is not enough; we must design a dosing regimen that ensures the antibiotic concentration in the body remains high enough to be effective. This advanced exercise [@problem_id:4616618] delves into the fields of pharmacokinetics and pharmacodynamics (PK/PD), challenging you to derive and apply a mathematical model to determine an effective antibiotic dose. Successfully completing this task illustrates how quantitative principles are used at the bedside to overcome the challenge posed by resistant pathogens.", "problem": "A patient with a bloodstream infection caused by Carbapenemase-Producing Enterobacterales (CRE) is being treated with a carbapenem administered by intermittent intravenous infusion. Carbapenems exhibit time-dependent killing, so the pharmacodynamic index of interest is the fraction of the dosing interval during which the free (unbound) plasma concentration exceeds the Minimum Inhibitory Concentration (MIC), denoted by $fT\\text{MIC}$. Starting from core pharmacokinetic and pharmacodynamic principles—specifically, the definition of Minimum Inhibitory Concentration (MIC), the concept of the unbound fraction ($f_u$), and a one-compartment model with first-order elimination—derive an expression for $fT\\text{MIC}$ under a repeated intermittent infusion regimen at steady state, and then compute the minimal dose required to achieve $fT\\text{MIC} \\ge 0.40$ for the following scientifically realistic scenario.\n\nAssume:\n- The carbapenem is infused every $\\tau = 8\\,\\mathrm{h}$, with an infusion duration of $T_{\\mathrm{inf}} = 3\\,\\mathrm{h}$.\n- The patient’s total body clearance is $CL = 10\\,\\mathrm{L/h}$ and the apparent volume of distribution is $V_d = 20\\,\\mathrm{L}$, implying a first-order elimination rate constant $k = CL/V_d$.\n- The fraction unbound is $f_u = 0.80$, and the pathogen’s MIC is $MIC = 2\\,\\mathrm{mg/L}$.\n- Let the dose per interval be $D$ (in $\\mathrm{mg}$). Define the zero-order input rate during infusion as $R_0 = D/T_{\\mathrm{inf}}$, and let $X = R_0/CL$.\n\nYou must:\n1. Derive, from first principles and standard one-compartment pharmacokinetics with zero-order input during infusion and first-order elimination, an analytic expression for $fT\\text{MIC}$ in terms of $X$, $k$, $T_{\\mathrm{inf}}$, and $\\tau$ at steady state, accounting for the free concentration threshold $C_{\\mathrm{th}} = MIC/f_u$.\n2. Use your derived expression to determine the minimal $D$ that achieves $fT\\text{MIC} \\ge 0.40$ in this patient. Assume steady state has been reached and that the time-above-threshold window begins during infusion and ends after infusion stops within the same dosing interval.\n3. Round your final numerical answer for $D$ to three significant figures. Express the final dose in $\\mathrm{mg}$.\n\nAll mathematical symbols and numbers in the derivation must be written in LaTeX. The final answer must be a single real-valued number. No units may appear inside the final boxed answer.", "solution": "The problem asks for the derivation of an expression for the pharmacodynamic index $fT\\text{MIC}$ and the subsequent calculation of a minimal required dose $D$ for a carbapenem antibiotic following a one-compartment pharmacokinetic model with intermittent intravenous infusion at steady state.\n\n### Step 1: Problem Validation\n\nThe problem is evaluated against the specified validation criteria.\n\n**1. Extraction of Givens:**\n- Regimen: Intermittent intravenous infusion at steady state.\n- Dosing interval: $\\tau = 8\\,\\mathrm{h}$.\n- Infusion duration: $T_{\\mathrm{inf}} = 3\\,\\mathrm{h}$.\n- Total body clearance: $CL = 10\\,\\mathrm{L/h}$.\n- Apparent volume of distribution: $V_d = 20\\,\\mathrm{L}$.\n- Elimination rate constant: $k = CL/V_d$.\n- Fraction unbound: $f_u = 0.80$.\n- Minimum Inhibitory Concentration: $MIC = 2\\,\\mathrm{mg/L}$.\n- Dose per interval: $D$ (in $\\mathrm{mg}$).\n- Zero-order input rate: $R_0 = D/T_{\\mathrm{inf}}$.\n- Defined variable: $X = R_0/CL$.\n- Target Pharmacodynamic Index: $fT\\text{MIC} \\ge 0.40$.\n- Core threshold definition: The effective concentration threshold is for the free drug, $C_f(t) = f_u C(t)$, so the target for the total concentration $C(t)$ is $C(t)  MIC/f_u$.\n- Constraint: The time-above-threshold window starts during the infusion and ends after the infusion stops within the same dosing interval.\n\n**2. Validation:**\n- **Scientific Grounding**: The problem is grounded in fundamental and widely accepted principles of pharmacokinetics and pharmacodynamics (PK/PD). The one-compartment model with zero-order input and first-order elimination is a standard model for intravenous infusions. The concept of $fT\\text{MIC}$ is a critical and established PK/PD index for time-dependent antibiotics like carbapenems. The parameters provided ($CL$, $V_d$, $\\tau$, etc.) are scientifically realistic for a human patient and this class of drugs.\n- **Well-Posedness**: The problem is well-posed. It provides sufficient information and a clear objective to derive a unique analytical expression and compute a specific numerical value. The constraint on when the concentration crosses the threshold properly bounds the problem.\n- **Objectivity**: The problem is stated in precise, quantitative, and objective language, free of ambiguity or subjective claims.\n\n**3. Verdict:**\nThe problem is valid as it is scientifically sound, well-posed, objective, and contains all necessary information for a rigorous solution.\n\n### Step 2: Derivation and Solution\n\nThe solution proceeds by first deriving the concentration profile at steady state, then deriving the expression for $fT\\text{MIC}$, and finally solving for the required dose $D$.\n\n**A. One-Compartment Model at Steady State**\n\nThe drug concentration $C(t)$ in a one-compartment model with zero-order infusion and first-order elimination is described by the following differential equations:\n$$\n\\frac{dC}{dt} = \\frac{R_0}{V_d} - kC(t) \\quad \\text{for } 0 \\le t \\le T_{\\mathrm{inf}} \\quad (\\text{infusion phase})\n$$\n$$\n\\frac{dC}{dt} = -kC(t) \\quad \\text{for } T_{\\mathrm{inf}}  t \\le \\tau \\quad (\\text{elimination phase})\n$$\nwhere $k = CL/V_d = (10\\,\\mathrm{L/h}) / (20\\,\\mathrm{L}) = 0.5\\,\\mathrm{h^{-1}}$.\n\nAt steady state, the concentration profile repeats every dosing interval $\\tau$. Let $C_{\\mathrm{ss,min}}$ be the trough concentration at the start of the interval ($t=0$) and $C_{\\mathrm{ss,peak}}$ be the peak concentration at the end of the infusion ($t=T_{\\mathrm{inf}}$). The general solution for the infusion phase starting from $C_{\\mathrm{ss,min}}$ is:\n$$\nC(t) = \\frac{R_0}{V_d k} \\left(1 - \\exp(-kt)\\right) + C_{\\mathrm{ss,min}}\\exp(-kt)\n$$\nAt $t=T_{\\mathrm{inf}}$, the concentration is $C_{\\mathrm{ss,peak}}$:\n$$\nC_{\\mathrm{ss,peak}} = \\frac{R_0}{V_d k} \\left(1 - \\exp(-kT_{\\mathrm{inf}})\\right) + C_{\\mathrm{ss,min}}\\exp(-kT_{\\mathrm{inf}})\n$$\nDuring the elimination phase, the concentration decays from $C_{\\mathrm{ss,peak}}$:\n$$\nC(t) = C_{\\mathrm{ss,peak}}\\exp(-k(t - T_{\\mathrm{inf}})) \\quad \\text{for } t  T_{\\mathrm{inf}}\n$$\nAt steady state, $C(\\tau) = C_{\\mathrm{ss,min}}$. Thus:\n$$\nC_{\\mathrm{ss,min}} = C_{\\mathrm{ss,peak}}\\exp(-k(\\tau - T_{\\mathrm{inf}}))\n$$\nSolving these two simultaneous equations for $C_{\\mathrm{ss,peak}}$ yields:\n$$\nC_{\\mathrm{ss,peak}} = \\frac{R_0}{V_d k} \\frac{1 - \\exp(-kT_{\\mathrm{inf}})}{1 - \\exp(-k\\tau)}\n$$\nUsing the problem's definition $X = R_0/CL = R_0/(V_d k)$, we can write:\n$$\nC_{\\mathrm{ss,peak}} = X \\frac{1 - \\exp(-kT_{\\mathrm{inf}})}{1 - \\exp(-k\\tau)}\n$$\n\n**B. Derivation of the $fT\\text{MIC}$ Expression**\n\nThe pharmacodynamic target is for the free concentration $C_f(t)$ to exceed $MIC$.\n$$\nC_f(t) = f_u C(t)  MIC\n$$\nThis is equivalent to the total concentration $C(t)$ exceeding a threshold concentration $C_{\\mathrm{th}}$:\n$$\nC(t)  \\frac{MIC}{f_u} \\equiv C_{\\mathrm{th}}\n$$\nGiven the problem's constraint, the concentration exceeds $C_{\\mathrm{th}}$ at a time $t_1$ during the infusion ($0  t_1  T_{\\mathrm{inf}}$) and falls below $C_{\\mathrm{th}}$ at a time $t_2$ after the infusion ends ($T_{\\mathrm{inf}}  t_2  \\tau$). The total time above threshold is $T_{MIC} = t_2 - t_1$. This can be calculated as the sum of the time above $C_{\\mathrm{th}}$ during the infusion and the time above $C_{\\mathrm{th}}$ after the infusion.\n\n1.  Time above $C_{\\mathrm{th}}$ after infusion ($T_{\\mathrm{inf}}$ to $t_2$):\n    The concentration decays from $C_{\\mathrm{ss,peak}}$ to $C_{\\mathrm{th}}$.\n    $$C_{\\mathrm{th}} = C_{\\mathrm{ss,peak}}\\exp(-k(t_2 - T_{\\mathrm{inf}}))$$\n    $$t_2 - T_{\\mathrm{inf}} = \\frac{1}{k}\\ln\\left(\\frac{C_{\\mathrm{ss,peak}}}{C_{\\mathrm{th}}}\\right)$$\n2.  Time above $C_{\\mathrm{th}}$ during infusion ($t_1$ to $T_{\\mathrm{inf}}$):\n    The concentration rises from $C_{\\mathrm{th}}$ at $t_1$ to $C_{\\mathrm{ss,peak}}$ at $T_{\\mathrm{inf}}$. The integrated equation for concentration during any sub-interval $[t_a, t_b]$ of the infusion phase is $C(t_b) = X - (X-C(t_a))\\exp(-k(t_b-t_a))$.\n    Here, $t_a=t_1$, $t_b=T_{\\mathrm{inf}}$, $C(t_a)=C_{\\mathrm{th}}$, and $C(t_b)=C_{\\mathrm{ss,peak}}$.\n    $$C_{\\mathrm{ss,peak}} = X - (X - C_{\\mathrm{th}})\\exp(-k(T_{\\mathrm{inf}} - t_1))$$\n    $$T_{\\mathrm{inf}} - t_1 = \\frac{1}{k}\\ln\\left(\\frac{X - C_{\\mathrm{th}}}{X - C_{\\mathrm{ss,peak}}}\\right)$$\n3.  Total time $T_{MIC}$ and fractional time $fT\\text{MIC}$:\n    $$T_{MIC} = (t_2 - T_{\\mathrm{inf}}) + (T_{\\mathrm{inf}} - t_1) = \\frac{1}{k}\\ln\\left(\\frac{C_{\\mathrm{ss,peak}}}{C_{\\mathrm{th}}}\\right) + \\frac{1}{k}\\ln\\left(\\frac{X - C_{\\mathrm{th}}}{X - C_{\\mathrm{ss,peak}}}\\right)$$\n    $$T_{MIC} = \\frac{1}{k}\\ln\\left(\\frac{C_{\\mathrm{ss,peak}}(X - C_{\\mathrm{th}})}{C_{\\mathrm{th}}(X - C_{\\mathrm{ss,peak}})}\\right)$$\n    The expression for the fractional time is:\n    $$fT\\text{MIC} = \\frac{T_{MIC}}{\\tau} = \\frac{1}{k\\tau} \\ln\\left(\\frac{C_{\\mathrm{ss,peak}}(X - C_{\\mathrm{th}})}{C_{\\mathrm{th}}(X - C_{\\mathrm{ss,peak}})}\\right)$$\n    where $C_{\\mathrm{ss,peak}} = X \\frac{1 - \\exp(-kT_{\\mathrm{inf}})}{1 - \\exp(-k\\tau)}$. This is the required analytic expression.\n\n**C. Calculation of the Minimal Dose $D$**\n\nWe need to find the minimal dose $D$ that achieves $fT\\text{MIC} \\ge 0.40$. Let $f_T = 0.40$. We solve for the variable $X$ and then find $D$.\nFrom the derived expression for $fT\\text{MIC}$:\n$$\n\\exp(f_T k \\tau) = \\frac{C_{\\mathrm{ss,peak}}(X - C_{\\mathrm{th}})}{C_{\\mathrm{th}}(X - C_{\\mathrm{ss,peak}})}\n$$\nLet $\\alpha = \\frac{1 - \\exp(-kT_{\\mathrm{inf}})}{1 - \\exp(-k\\tau)}$. Then $C_{\\mathrm{ss,peak}} = X\\alpha$. Substituting this in:\n$$\n\\exp(f_T k \\tau) = \\frac{X\\alpha(X - C_{\\mathrm{th}})}{C_{\\mathrm{th}}(X - X\\alpha)} = \\frac{\\alpha(X - C_{\\mathrm{th}})}{C_{\\mathrm{th}}(1-\\alpha)}\n$$\nNow, we solve for $X$:\n$$\nC_{\\mathrm{th}}(1-\\alpha)\\exp(f_T k \\tau) = \\alpha(X - C_{\\mathrm{th}}) = \\alpha X - \\alpha C_{\\mathrm{th}}\n$$\n$$\n\\alpha X = \\alpha C_{\\mathrm{th}} + C_{\\mathrm{th}}(1-\\alpha)\\exp(f_T k \\tau)\n$$\n$$\nX = \\frac{C_{\\mathrm{th}}}{\\alpha}\\left[ \\alpha + (1-\\alpha)\\exp(f_T k \\tau) \\right]\n$$\n\nNow, we substitute the numerical values:\n- $k = 0.5\\,\\mathrm{h^{-1}}$\n- $\\tau = 8\\,\\mathrm{h}$\n- $T_{\\mathrm{inf}} = 3\\,\\mathrm{h}$\n- $MIC = 2\\,\\mathrm{mg/L}$\n- $f_u = 0.80$\n- $C_{\\mathrm{th}} = MIC/f_u = (2\\,\\mathrm{mg/L}) / 0.80 = 2.5\\,\\mathrm{mg/L}$\n- $f_T = 0.40$\n- $CL = 10\\,\\mathrm{L/h}$\n\nFirst, calculate the constants:\n- $k T_{\\mathrm{inf}} = 0.5 \\times 3 = 1.5$\n- $k \\tau = 0.5 \\times 8 = 4.0$\n- $f_T k \\tau = 0.40 \\times 4.0 = 1.6$\n- $\\alpha = \\frac{1 - \\exp(-1.5)}{1 - \\exp(-4.0)} \\approx \\frac{1 - 0.223130}{1 - 0.018316} \\approx \\frac{0.776870}{0.981684} \\approx 0.791361$\n- $1 - \\alpha \\approx 1 - 0.791361 = 0.208639$\n- $\\exp(f_T k \\tau) = \\exp(1.6) \\approx 4.953032$\n\nNow calculate $X$:\n$$\nX \\approx \\frac{2.5}{0.791361}\\left[ 0.791361 + (0.208639)(4.953032) \\right]\n$$\n$$\nX \\approx 3.159306 \\left[ 0.791361 + 1.033344 \\right]\n$$\n$$\nX \\approx 3.159306 \\times 1.824705 \\approx 5.76451\\,\\mathrm{mg/L}\n$$\n\nFinally, calculate the dose $D$ from $X$:\n$X = \\frac{R_0}{CL} = \\frac{D/T_{\\mathrm{inf}}}{CL} \\implies D = X \\cdot CL \\cdot T_{\\mathrm{inf}}$\n$$\nD = (5.76451\\,\\mathrm{mg/L}) \\times (10\\,\\mathrm{L/h}) \\times (3\\,\\mathrm{h})\n$$\n$$\nD = 172.9353\\,\\mathrm{mg}\n$$\nThe problem requires rounding the final answer to three significant figures.\n$$\nD \\approx 173\\,\\mathrm{mg}\n$$", "answer": "$$\\boxed{173}$$", "id": "4616618"}]}